Consensus revenue is $220.02 million with an expected loss of $2.52 per share, as the current $97.54 stock price remains well below the $133.13 analyst target.
Investors are primarily focused on the company’s strategic transition toward its oncology pipeline to offset the rapid decline of legacy COVID-19 vaccine income.
With over 20 programs now in Phase 2 or 3 trials, BioNTech is leveraging its massive cash reserves to accelerate candidates like the BNT327 bispecific antibody. Analysts will scrutinize management’s updates on clinical timelines and the impact of aggressive R&D spending, which is projected to reach up to €2.5 billion this year.